Member Info for ProfessorZ

Nice story! What about the one with the car jumping the hedge?

I've always wanted a boat for those odd days on the south coast when the sea is flat and you can just take yourself away from it all. Simple pleasures but, for one reason or another, never got around to it. Interestingly when I was with my eldest son last week he seemed keen on the idea of a boat too.. must run in the blood!

I'm patiently waiting here for something to happen, still optimistic and fortunately not in any rush for the money!

Great board this, makes me feel quite youthful. Guess the BoD are actually doing us a favour by hanging things out otherwise we'd all be gone our different ways, cruising off into the sunset in or on our preferred vehicle.

Now one thing I've always fancied something that floats...

How'd you win a car for £10 Bignose?

Morning bignose/MattD,

It certainly appears to be a very sensitive stock at the moment which as Matt suggests could be down to one large buyer. Volumes will undoubtedly pick up again in the future, hopefully moving the stock further north - we need a trigger event for this - something more than what we already know. Now would be a very useful time to make an announcement on the illusive RoW licenses... Failing that it's strong sales figures with US approval quite a way down the road, but enough to keep the interest long term. Given that we are in pharmaceutical development, there is always the possibility of other product development.

I cannot imagine the BoD have really been sitting on their hands all this time, so if we get any of this before the end of autumn, I'll forgive Mr Gibson. Call me fickle, but at least I have it in me to forgive.

Can anybody see why this moved north at 11:20 HK time?

I think we are agreed that we can expect another hit on the p&l, writing-off the gain made on the PLE acquisition. All numbers, no real cash behind any of it.

Although we should be seeing a reduction in losses because we really have received money from Recordati in the territories already launched. I wonder how that will be treated in the accounts as arguably this should also be subject to the same amortisation rules as the write down of PLE.

I'm not sure how much choice we had about including PLE on the RP balance sheet but the amount was as a result of the valuation which was an internal exercise. Remembering back to the takeover, the figures were somewhat academic given the base share price of RP at the time. Nevertheless, it is what it is and I would argue that any potential takeover would have to at least acknowledge the valuation that is on the balance sheet, even if it is reducing every year.

I would argue however that we are amortising PLE over a shorter time period than necessary. I would also suggest that, as PLE was acquired prior to US approval, upon approval the balance sheet might substantially increase as a result.

For me at the moment, I'd far rather see a healthy cash balance and positive cashflow. Operationally I'm happy that US approval is moving forward. Until then we may be pleasantly surprised with European sales which we all, including the market are perhaps viewing with lower expectations than had we enjoyed a more active marketing campaign.

Just seeing how things are panning-out, I can't help but think that selling PLE was always the objective of JG. We are in a strange position at the moment, between EU launch and US approval. Time will tell, but for me at least, I was more comforted with the last press release than I will be concerned about the profit warning.

Those row license deals absolutely fell off the metaphorical cliff. RP paid Sharwoods a considerable sum to get rid, with absolutely no benefit. Are we even trying to get a new partner?

An update would be helpful, but it appears that policy is to inform after the event these days.

For the record, I continue to subscribe to the takeover theory post UK launch. It was the most peculiar chain of events that only could be explained by a large single entity swallowing-up all of the substantial selling or a systems cock-up in the HK dealing rooms. For me the volumes both put it out of reach of an average p&d, and this would have been pretty well scuppered by the Maven exit.

We also know that it is possible to stay hidden from holdings declarations.

If there is another large holder out there, they have certainly gone quiet though, at best consolidating their holding. In one sense the dust settled a long time ago but we know things have tightened -up with the share moving upwards on relatively low volumes. Another onslaught from a single buyer and this could easily push through HK$1.

Maybe we'll have to wait until US approval now as there seems little point acquiring this before such a time if we are looking solely at Fortacin, but there may be some links with the bigger picture - Recordati.

Wouldn't it be good to know all of the facts. What are other's views on the takeover theory?

Not sure of the complexities of HK listed company law, but it would need to be voted on at the AGM or an EGM could be called tabling a motion to elect a nominated individual onto the board.

Two problems. Firstly the substantial holding of JM would undoubtedly vote against.

Second problem would be finding a volunteer.

Technically, as shareholders we could put in whoever we would like.

Great find!

Pom, N4P has highlighted the difficulties that new drug developments bring with it, I have to admit forgetting about that little gem, with the Dr. associated with RP, we at least have a track record in the ED drug development. N4P's failure therefore could be to our benefit in the longer term.

What do we know about our development timeline for this one?

bunion, I absolutely agree. BoD complacency.

I thought more of JG, he seems a clever enough man yet his recent history leaves us all questioning the underlying truth. I am prepared to forgive the 6 dose canister problems - clearly harder than it sounds, and to his credit, he used to communicate whilst being involved with PLE. Despite his recent blunders, I still trust the man, but the lack of anything coming out of him or the company regarding responses to emails or developments makes me question what he is actually doing these days.

Another beautiful RNS.

Exactly what I thought. Fortacin is a tested and proven product - N4P, even though they are not competing with Fortacin, are going to need more cash to develop alternatives - we are already here and should be maximising the potential.

Despite de-risking my N4P holding, I've got shares in both, so at least I feel my statement is balanced.

So it's a shame to see last week's gains being steadily eroded. My feeling is that we are worth much more but nobody other than holders (past and present) know we even exist. I wouldn't mind betting half of Singapore still think this is a mining company.

No no no no :D I know you meant that, what I meant was I thought they'd got rid of their minions/goffas etc when they got rid of their urology!!! Yeeeears ago :D

"Didn't think that they"

Didn't they needed lab rats, thought they'd knocked that on the head years ago? Keep posting the questions though!

No reply to my email btw, looking forward to the next update as interest is mounting on the trading front. Easy to forget that we are sitting on the only fully EU approved PE spray treatment in the world. If only we'd enlisted the assistance of a quality marketing/advertising partner, I'm sure we'd be flying - would be money well spent methinks.

Anybody seen any examples of Recordati marketing in the countries of launch?

If the market ever wakes up to the value here we are all going to be laughing - this moves on very low volumes. Thanks for the intel. Sider.

No evidence that this drop was as a result of a sell-off. Looks like an opportunity to pick some up cheap to me.

Filled up a day's worth of posts though :D

What were you on this morning???